PHASE-II STUDY OF CARBOPLATIN AND ETOPOSIDE AS A FIRST-LINE REGIMEN IN PATIENTS WITH METASTATIC BREAST-CANCER

被引:9
作者
VANDERGAAST, A
BONTENBAL, M
PLANTING, AST
KOK, TC
SPLINTER, TAW
机构
[1] DANIEL DEN HOED KLIN,ROTTERDAM,NETHERLANDS
[2] ROTTERDAM CANC INST,DEPT MED ONCOL,ROTTERDAM,NETHERLANDS
关键词
METASTATIC BREAST CANCER; CHEMOTHERAPY; CARBOPLATIN; ETOPOSIDE;
D O I
10.1093/oxfordjournals.annonc.a059020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The data available on the role of carboplatin and etoposide in breast cancer, especially in patients with no or minimal prior therapy are limited. Patients and methods: We performed a phase II study with carboplatin and etoposide as first line treatment in 34 patients with metastatic breast cancer. The treatment regimens was carboplatin 300 mg/m(2) day 1, and etoposide 100 mg/m(2) days 1, 3 and 5, every four weeks. Results: Of 33 evaluable patients, 2 achieved complete responses (6%) lasting 4 and 5 months, 7 patients (21%) achieved partial responses with a median duration of 6+ (range 5-8) months, 15 patients had stable disease, and 9 progressed during treatment. The major toxicity was myelosuppression. WHO grades 3 or 4 leukocytopenia or thrombocytopenia were seen in 15 and 10 patients, respectively. One formally ineligible patient with an impaired renal function died 14 days after the start of treatment because of a septicaemia in the presence of a grade 4 leukocytopenia. Besides this patient no other patient presented with granulocytopenic fever. Conclusion: In view of the observed response rate of 27% (95% confidence interval 11%-43%) we think that carboplatin and etoposide given in this dose and schedule has probably no clear advantage over the more commonly used regimens.
引用
收藏
页码:858 / 860
页数:3
相关论文
共 10 条
[1]  
BOOTH BW, 1985, CANCER TREAT REP, V69, P919
[2]   CISPLATIN AND ETOPOSIDE AS 1ST-LINE CHEMOTHERAPY FOR METASTATIC BREAST-CARCINOMA - A PROSPECTIVE RANDOMIZED TRIAL OF THE ITALIAN ONCOLOGY GROUP FOR CLINICAL RESEARCH [J].
COCCONI, G ;
BISAGNI, G ;
BACCHI, M ;
BONI, C ;
BARTOLUCCI, R ;
CECI, G ;
COLOZZA, MA ;
DELISI, V ;
LOTTICI, R ;
MOSCONI, AM ;
PASSALACQUA, R ;
TONATO, M .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :664-669
[3]  
KALORIC K, 1991, CANCER CHEMOTHER PHA, V27, P409
[4]   CARBOPLATIN - AN ACTIVE-DRUG IN METASTATIC BREAST-CANCER [J].
MARTIN, M ;
DIAZRUBIO, E ;
CASADO, A ;
SANTABARBARA, P ;
VEGA, JML ;
ADROVER, E ;
LENAZ, L .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :433-437
[5]  
MARTIN M, 1991, SEMIN ONCOL, V18, P23
[6]  
NICHOLS CR, 1992, SEM ONCOL S13, V6, P67
[7]   CARBOPLATIN IN THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II STUDY USING A PHARMACOKINETICALLY GUIDED DOSE SCHEDULE [J].
OBRIEN, MER ;
TALBOT, DC ;
SMITH, IE .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2112-2117
[8]  
WANDER HE, 1989, CANCER CHEMOTH PHARM, V24, P261
[9]  
WANDER HE, 1988, J CANCER RES CLIN, V114, pS60
[10]  
1979, OFFSET PUBLICATION, V48